News

BriaCell Announces Four Clinical Data Presentations at ASCO 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
Seeking Alpha4d
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
The ASCO Annual Meeting showcases the most cutting-edge research in clinical ... contained in this presentation do not constitute profit forecast by the Company’s management.
Morningstar5d
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical ... The data will be presented as a late-breaking oral presentation during the Research Forum ...
Nasdaq4d
Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting
Xilio Therapeutics, Inc. announced that it will present updated data from its Phase 2 clinical trial on vilastobart ... Annual Meeting in Chicago. The presentation is scheduled for May 31 ...